context: Also, the detectors in current systems are too large to be used in trans-rectal probes.
answer_0: Nonetheless the new cadmium zinc telluride (CZT) -based gamma camera is small enough for trans-rectal prostate cancer diagnosis, after the patient is injected with a tracer radiopharmaceutical.
answer_1: For example the new cadmium zinc telluride (CZT) -based gamma camera is small enough for trans-rectal prostate cancer diagnosis, after the patient is injected with a tracer radiopharmaceutical.
answer_2: Instead, the new cadmium zinc telluride (CZT) -based gamma camera is small enough for trans-rectal prostate cancer diagnosis, after the patient is injected with a tracer radiopharmaceutical.
answer_3: In contrast, the new cadmium zinc telluride (CZT) -based gamma camera is small enough for trans-rectal prostate cancer diagnosis, after the patient is injected with a tracer radiopharmaceutical.
answer_4: Once, the new cadmium zinc telluride (CZT) -based gamma camera is small enough for trans-rectal prostate cancer diagnosis, after the patient is injected with a tracer radiopharmaceutical.
answer_5: Currently, the new cadmium zinc telluride (CZT) -based gamma camera is small enough for trans-rectal prostate cancer diagnosis, after the patient is injected with a tracer radiopharmaceutical.
answer_6: Optionally, the new cadmium zinc telluride (CZT) -based gamma camera is small enough for trans-rectal prostate cancer diagnosis, after the patient is injected with a tracer radiopharmaceutical.
answer_7: In particular, the new cadmium zinc telluride (CZT) -based gamma camera is small enough for trans-rectal prostate cancer diagnosis, after the patient is injected with a tracer radiopharmaceutical.
answer_8: Often, the new cadmium zinc telluride (CZT) -based gamma camera is small enough for trans-rectal prostate cancer diagnosis, after the patient is injected with a tracer radiopharmaceutical.
answer_9: Second, the new cadmium zinc telluride (CZT) -based gamma camera is small enough for trans-rectal prostate cancer diagnosis, after the patient is injected with a tracer radiopharmaceutical.